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Background: Parkinson’s disease (PD) is a progressive neurodegenerative disorder which
may be misdiagnosed with atypical conditions such as Multiple System Atrophy (MSA),
due to overlapping clinical features. MicroRNAs (miRNAs) are small non-coding RNAs
with a key role in post-transcriptional gene regulation. We hypothesized that identification
of a distinct set of circulating miRNAs (cmiRNAs) could distinguish patients affected
by PD from MSA and healthy individuals. Results. Using TaqMan Low Density Array
technology, we analyzed 754 miRNAs and found 9 cmiRNAs differentially expressed in PD
and MSA patients compared to healthy controls. We also validated a set of 4 differentially
expressed cmiRNAs in PD and MSA patients vs. controls. More specifically, miR-339-5p
was downregulated, whereas miR-223∗, miR-324-3p, and mir-24 were upregulated in
both diseases. We found cmiRNAs specifically deregulated in PD (downregulation of
miR-30c and miR-148b) and in MSA (upregulation of miR-148b). Finally, comparing MSA
and PD, we identified 3 upregulated cmiRNAs in MSA serum (miR-24, miR-34b, miR-148b).
Conclusions. Our results suggest that cmiRNA signatures discriminate PD from MSA
patients and healthy controls and may be considered specific, non-invasive biomarkers
for differential diagnosis.
Keywords: Parkinson’s disease, atypical parkinsonian disorders, Multiple System Atrophy, microRNAs, circulating
microRNAs, early diagnosis
BACKGROUND
Parkinson’s disease (PD) is a neurodegenerative disorder charac-
terized by rigidity, tremor, bradykinesia, and postural instability.
Clinical diagnosis is challenging and misdiagnosis rate is com-
prised between 10 and 30% in early stages mainly due to failure
to recognize atypical parkinsonism (Poewe and Wenning, 2002).
The commonest atypical form isMultiple SystemAtrophy (MSA),
a sporadic neurodegenerative disorder characterized by neuronal
cell loss and gliosis in specific brain areas including the basal gan-
glia (Paik et al., 2010). Early differentiation between PD andMSA
has clinical, therapeutic and prognostic consequences and may
be difficult, if based solely on clinical examination (Galvin et al.,
2001; Campbell and Choy, 2012). Specific imaging abnormalities
can be present but only when the symptoms are fully established
(Ghaemi et al., 2002), while identification of disease-specific
and minimally invasive biomarkers would be required for early
diagnosis. Recent evidence suggests that the post-transcriptional
regulation is an important process in PD pathophysiology (Imai
et al., 2008; Blackinton et al., 2009; Tain et al., 2009; Harraz et al.,
2011). MicroRNAs (miRNAs) are small non-coding RNAs, which
have been identified as post-transcriptional regulators of gene
expression (Graves and Zeng, 2012); miRNAs can inhibit protein
coding genes by affecting mRNA translation and/or stability.
MiRNAs play important regulatory roles in many cellular pro-
cesses as cell replication, differentiation and neoplastic transfor-
mation (Etheridge et al., 2011; Ragusa et al., 2012) and in granting
the survival of mature neurons and their functions (Hong et al.,
2013). Recent studies have shown that some miRNAs are differ-
entially expressed (DE) in human brain and may regulate the
expression of genes associated with Alzheimer’s disease (AD) and
PD (Schonrock et al., 2010; Miñones-Moyano et al., 2011; Bekris
et al., 2013; Cho et al., 2013; Lau et al., 2013). PD with and
without dementia revealed lower levels of miR-205 in the frontal
cortex and striatum, if compared to healthy controls (Cho et al.,
2013), while another study showed that miR-34b and mir34c
are downregulated in several PD brain areas (Miñones-Moyano
et al., 2011). A signature of 18 miRNAs under-expressed in PD
peripheral blood mononuclear cells has been suggested to distin-
guish patients from controls (Martins et al., 2011). Other studies
have identified specific miRNAs targeting and down-regulating
the expression of PD-related genes and demonstrating a recipro-
cal relationship between PD-related genes and miRNA processing
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(Heman-Ackah et al., 2013). Junn et al. showed higher miR-7
levels in the substantia nigra and striatum of mice compared to
cerebral cortex and cerebellum. MiR-7 levels were found to be 40
times higher in neurons than in astrocytes (Junn et al., 2009).
Moreover alpha synuclein was detected in neurons, but not in
astrocytes (Junn et al., 2009). Doxakis et al. described a simi-
lar alpha synuclein regulation by miR-7 and miR-153 (Doxakis,
2003). Recent studies have also reported deregulated miRNAs lev-
els in PD patients plasma compared to normal subjects (Khoo
et al., 2012; Cardo et al., 2013). Circulating miRNAs (cmiRNAs)
possess many key features typical of reliable biomarkers, since
they are easily detectable, stable in many body fluids, and eas-
ily measurable by PCR. Finally, alterations of several cmiRNA
levels in plasma, serum, urine, and saliva have been associated
with different diseases, as acute myocardial infarction, conges-
tive heart failure, different types of cancer, and multiple sclerosis
(Etheridge et al., 2011). A panel of serum cmiRNAs (mir-29, mir-
29c, mir-19a/b) were downregulated in carriers of LRKK2G2019S
mutation and in idiopathic PD patients compared to healthy
controls (Botta-Orfila et al., 2014).
In this study, for the first time, we tested the hypothesis that
specific panels of cmiRNAs could differentiate PD from MSA
patients and represent a potential biomarker to be applied in
clinical setting.
MATERIALS AND METHODS
PATIENTS AND SAMPLE COLLECTION
Study participants were recruited from the Parkinson Unit at the
San Camillo Hospital (Venice, Italy) and the 1st Neurology Clinic
at the University Hospital of Padua (Padua, Italy). In the dis-
covery set, we enrolled six patients affected by PD (55 ± 5.5
years mean ± s.e.m.), six patients affected by MSA, parkinso-
nian subtype P (MSA-P) (63± 10 years mean ± s.e.m.), and
three patients affected by MSA, cerebellar dysfunction subtype
C (MSA-C) (62 ± 2 years mean ± s.e.m.). Healthy controls
included five age- and ethnicity-matched subjects (59 ± 3.08
years mean ± s.e.m.; range = 55–63), with no history of neuro-
logical or psychiatric diseases. Furthermore, we excluded subjects
with inflammatory and systemic diseases, as diabetes and other
cardiovascular diseases. In the validation set, we enrolled 75 sub-
jects: 25 PD, 25 MSA and 25 healthy controls. All PD patients
were diagnosed according to the UK Brain Bank Criteria (Hughes
et al., 1992) Clinical diagnosis was confirmed by two indepen-
dent and certified neurologists. Inclusion criteria were: disease
duration of less than 6 years from diagnosis, mild to moderate
disease stage (Hoehn and Yahr score > 2.5), no significant cog-
nitive deficit (Mini Mental State Examination (MMSE); score >
26) and age between 46 and 60 years (Hoehn and Yahr, 1967;
Folstein et al., 1975). All MSA patients were diagnosed accord-
ing to Gilman’s criteria and the diagnosis was confirmed by
two independent certified neurologists (Gilman et al., 1998). We
included MSA patients over the age of 50 and clinical sever-
ity was evaluated with the Unified Multiple System Atrophy
Rating Scale (Wenning et al., 2004). Exclusion criteria for the
selection of PD and MSA patients were the same and included:
presence of other neurological disorders, PD and neurodegen-
erative disease familiarity, clinical dementia (based on DSM-IV
Table 1 | Clinical characteristics of patients and healthy controls.
Characteristics PD MSA Healthy controls
N 25 25 25
Male/Female 13 (12) 12 (13) 13 (12)
UPDRS 37.05 (9.8) 37.88 (12.88) –
LDED 730.48 (392.8) 708.27 (319.35) –
Dopamine agonist 126.7 (127) 75 (82.11) –
H and Y 3 (0.03) 3 (0.08) –
LDED, L-dopa daily equivalent dose; H and Y, Hoehn and Yahr scale.
criteria), early and late disease onset, presence of concomitant
systemic diseases, as diabetes and other cardiovascular diseases
and MMSE < 26 corrected for age and education. The demo-
graphic data (age and gender) and neurological details are shown
in Table 1. All patients had been tested for the G2019S-LRKK2
and PARK2 and SNCA mutations and none of those included in
this study was homozygous or heterozygous for these mutations.
All enrolled patients underwent fasting venous blood sampling.
Blood samples were obtained by vein puncture using dry vacu-
tainer tubes (BD Biosciences, Italy). The blood samples were
processed by the Laboratory of Molecular Biology of IRCCS
San Camillo. The samples were processed for serum isolation
within 2 h after withdrawal. Whole blood was left to stand for
about 30′ at 20◦C before being centrifuged at 3000 rpm for 15′ at
4◦C. Serum was divided into aliquots, and stored at -80◦C until
analysis.
RNA isolation, reverse transcription, and miRNA profiling by
TaqMan Low density Array
Serum samples were centrifuged at 2000 rpm for 10′ to pellet
and remove any circulating cell or debris. miRNAs were extracted
from 400μl of serum samples by using Qiagen miRNeasy mini
kit (Qiagen, GmbH, Hilden, Germany), according to Qiagen sup-
plementary protocol for purification of small RNAs from serum
and plasma, and finally eluted in 30μl volume of elution buffer
(Ragusa et al., 2013). RNAs were quantified by fluorometer and
spectrophotometer. To profile the transcriptome of 754 miRNAs,
3.2μl of serum RNAs (corresponding to about 20 ng of RNA)
were retrotranscribed and pre-amplified, according to the man-
ufacturer’s instructions. Pre-amplified products were loaded onto
TLDAs, TaqMan HumanMicroRNA Array v3.0 A and B (Applied
Biosystems | Life Technologies™ Monza, Italy). PCRs on TLDAs
were performed on 7900HT Fast Real Time PCR System (Applied
Biosystem | Life Technologies™ Monza, Italy). Result validation
was obtained by single TaqMan assays (Applied Biosystems | Life
Technologies™ Monza, Italy) using the same amount of serum
miRNAs according to the manufacturer’s instructions.
DATA ANALYSIS
To obtain an accurate miRNA profiling, we used the global
median normalization method. Similarly to microarray analysis,
Ct values from each sample were normalized to the median
Ct of the array (Ragusa et al., 2010). Moreover, by computing
the Pearson correlation among the Ct medians and means of
each array and Ct of each miRNA, we identified two miRNAs
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that showed an expression profile closer to the median and
mean of TLDAs, i.e., miR-17 and miR-151-3p. These miRNAs
also resulted among the most stable in TLDAs by applying two
different methods [DataAssist v.3 software (Applied Biosystems |
Life Technologies™ Monza, Italy)] and geNorm Algorithm
(http://medgen.ugent.be/∼jvdesomp/genorm/). Accordingly,
miR-17 and miR-151-3p were used as reference genes for vali-
dation by single TaqMan assays. Expression fold changes were
calculated by the 2−CT method. DE miRNAs were identified
by Significance of Microarrays Analysis (SAM) computed by
Multi experiment viewer v4.8.1 (http://www.tm4.org), applying
a two-class unpaired test among Cts and using a p-value
based on 100 permutations and imputation engine: K-nearest
neighbors (10 neighbors). False discovery rate<0.15 was used
as correction for multiple comparisons. We accepted as reliable
only DE miRNAs concordant by using all endogenous controls.
Expression data in “Results” are shown as average relative
quantity (RQ) of all RQ values, calculated with each endogenous
control respect to normal controls. RQ values< 1 were converted
to negative fold changes by following the formula: -1/RQ. The
Wilcoxon signed-rank test (p < 0.05) was applied to statistically
evaluate expression differences between patients affected by PD
or MSA and healthy controls in single TaqMan validation assays.
miRNA TARGET PREDICTION
In order to increase data strength, DE miRNA targets were ana-
lyzed by a combination of two different approaches. By interpo-
lating 11 prediction tools (http://mirecords.biolead.org), a first
series of predicted and experimentally validated DE miRNA tar-
gets was extracted frommiRecords. To improve our prediction, an
additional filtering was performed by using starBase, a database
for predicted miRNA–target interactions, overlapped with data
from Argonaute cross-linked immunoprecipitation sequencing
(CLIP-Seq) (Yang et al., 2011). CLIP-Seq experiments are based
on crosslinking between RNA and proteins, followed by immuno-
precipitation coupled to high-throughput sequencing. The appli-
cation of this technique is applied to identify miRNA binding
sites.
GENE ONTOLOGY ANALYSIS
The identification of statistically significant Gene Ontologies of
miRNA targets was obtained by using FatiGo (Biological Process)
from Babelomics 4.2 server (http://babelomics.bioinfo.cipf.es/).
We used the gene functional classification tool DAVID (http://
niaid.abcc.ncifcrf.gov) to identify tissue-specific expression of
miRNA targets.
Ethics statement
This study was conducted according to the Declaration of
Helsinki and was approved by the ethics committee of IRCCS San
Camillo, Venice (Italy). A written informed consent was obtained
from all the patients participating in this study.
RESULTS
EXPRESSION PROFILES BY TaqMAN LOW DENSITY ARRAYS
To determine whether there was a unique PD- and MSA-
associated miRNA profile, which could be identified in serum, we
first tested 20 samples (discovery set) using TaqMan Low Density
Array technology. We initially determined the expression profile
of 754 miRNAs in serum of 6 PD patients and 9 MSA (6 with
MSA-P and 3 subjects affected by MSA-C). These serum pro-
files were compared with those of five normal subjects. From
754 screenable miRNAs of TLDA, we identified 324 circulating
miRNAs in all our serum samples. Delta Cts obtained from these
profiles are shown in complementary data 1 and graphically plot-
ted in complementary data 2. By applying SAM method, we
highlighted differentially expressed (DE) miRNAs by perform-
ing four comparisons among these miRNA profiles: (a) whole
cohort of pathological samples (MSA + PD) vs. the healthy ones;
(b) PD samples vs. controls; (c) MSA samples vs. controls; MSA
samples vs. PD samples. We found 8 DE miRNAs (3 downreg-
ulated, 5 upregulated) from the first comparison; 9 DE miRNAs
from the second comparison (4 downregulated, 5 upregulated);
12 DE miRNAs from the third comparison (3 downregulated,
9 upregulated); 5 DE miRNAs from MSA vs. PD comparison
(1 downregulated, 4 upregulated). These data are reported in
Table 2.
DIFFERENTIAL EXPRESSION OF miRNAS AMONG PD AND MSA
PATIENTS AND HEALTHY CONTROLS
In order to validate these findings, we subsequently tested the
expression of DEmiRNAs in the same samples analyzed by TLDA
and in a separate and independent cohort of patients (25 PD and
25 MSA) and 25 healthy controls by using single TaqMan assays
and applying theWilcoxon rank-sum test (p < 0.05). Data valida-
tion by single TaqMan assays resulted in identification of upreg-
ulation for miR-24, miR-223∗, miR-324-3p and downregulation
for miR-339-5p (Table 2, Figure 1).
SPECIFIC DYSREGULATION OF cmiRNAS IN PD PATIENTS COMPARED
WITH HEALTHY CONTROLS
In the second comparison, we pinpointed DE miRNAs specific
for PD (Table 2). We initially identified nine DE miRNAs by
high throughput profiling, but only five were successfully val-
idated: miR-24, miR-223∗, miR-324-3p resulted upregulated in
PD patients with respect to healthy controls, while miR-30c and
miR-148b were downregulated (Table 2, Figure 2). The downreg-
ulation of miR-30c and miR-148b in PD patients compared to
healthy controls seemed to be specific for PD.
cMiRNAs DIFFERENTIALLY EXPRESSED BETWEEN MSA PATIENTS
AND HEALTHY CONTROLS
In the third comparison, we identified DE miRNAs specific for
MSA patients: the initial set of 12 DEmiRNAs was further filtered
by single assay validation. This confirmed overexpression of miR-
24, miR-148b, miR-223∗, miR-324-3p, and downmodulation of
miR-339-5p (Table 2, Figure 3). Interestingly, upregulation of
miR-24, miR-223∗, and miR-324-3p was significant in PD and
MSA subjects compared with healthy controls, both grouped
together or analyzed as specific disease groups. These data sug-
gest that deregulation of these circulatingmiRNAs could originate
from pathological features common to both diseases.
It is interesting to note that downregulation of miR-339-5p
was detected for PD + MSA vs. controls (Ctrl) Unexpectedly,
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Table 2 | DE MiRNAs in PD and MSA patients compared to healthy controls.
MSA+PD vs. CTRL PD vs. CTRL MSA vs. CTRL MSA vs. PD
DE miRNAs Average FC DE miRNAs Average FC DE miRNAs Average FC DE miRNAs Average FC
(TLDA) (single assay) (TLDA) (single assay) (TLDA) (single assay) (TLDA) (single assay)
(p-value) (p-value) (p-value) (p-value)
mir-24 7.2 (0.00004) mir-24 2.94 (0.03) miR-24 4.45 (0.00008) miR-24 2.35 (0.00004)
mir-34b 1.59 (0.375) miR-30c −1.53 (0.036) mir-29c 1.22 (0.102) miR-34b 3.9 (0.012)
miR-223* 2.31 (0.001) miR-34b 1.76 (0.07) miR-148b 1.78 (0.00009) miR-148b 3.19 (0.0006)
miR-324-3p 3.29 (0.0001) miR-148b −1.53 (0.039) mir-223* 3.35 (0.0003) miR-339-5p 1.34 (0.34)
miR-339-5p −2.57 (0.007) miR-223* 2.09 (0.006) miR-324-3p 4.04 (0.0002) mir-1274A −1.12 (0.485)
mir-652 −1.29 (0.202) miR-324-3p 1.89 (0.036) miR-339-5p −1.64 (0.032)
mir-744 −1.53 (0.378) mir-339-5p −1.88 (0.358) mir-483-5p 1.16 (0.407)
miR-1274A 3.42 (0.31) mir-652 −1.63 (0.21) mir-652 −1.53 (0.244)
miR-1274A 4.34 (0.12) mir-744 −1.43 (0.402)
miR-1274A 2.45 (0.09)
mir-1274B 1.89 (0.086)
miR-1291 4.45 (0.052)
Differentially Expressed miRNAs identified in this study by TLDAs and their validation by single TaqMan assays. DE, Differentially Expressed; FC, Fold Change.
MiRNAs statistically validated by single assays are typed in bold text. *Part of the name of the microRNA according with microRNA nomenclature.
FIGURE 1 | Box and Whisker plot of DE cmiRNAs validated after single
TaqMan assays in PD and MSA patients compared to controls. Values
on the y-axis are reported as Ct × (−1). White boxes: healthy controls;
gray boxes: PD and MSA patients. The bottom and top of the box are the
first and third quartiles; the band inside the box is the second quartile (the
median); the ends of the whiskers represents minimum and maximum
values of the data. Samples analysed: 30 CTRL; 31 PD + 34 MSA.
Statistical significance was evaluated by the Wilcoxon rank sum test
(p < 0.05). ∗Part of the name of the microRNA according with microRNA
nomenclature.
following the specific-disease analysis, this miRNA was differ-
entially expressed only in MSA vs. Ctrl. This statistical ambi-
guity may be due to the homogenization of expression data by
mixing different pathological groups, although phenotypically
similar.
MiRNAs DIFFERENTIALLY EXPRESSED IN PD AND MSA PATIENTS
In the fourth analysis, we directly compared the cmiRNA tran-
scriptome of MSA patients with that of PD patients in search
of discriminating miRNAs between the two pathological phe-
notypes. Statistical analysis of whole miRNA profiles initially
showed five DE miRNAs. We confirmed the deregulation of
three of them through single Taqman assays: miR-24, miR-34b,
and miR-148b were upregulated in serum of MSA patients with
respect to PD patients (Table 2, Figure 4).
On the other hand, upregulation of miR-148b, observed only
in MSA patients if compared to PD subjects, seemed to be a valid
discriminating factor.
Frontiers in Cellular Neuroscience www.frontiersin.org June 2014 | Volume 8 | Article 156 | 4
Vallelunga et al. cmiRNAs in PD and MSA
FIGURE 2 | Box and Whisker plot of DE cmiRNAs validated
after single TaqMan assays in PD patients compared with
healthy controls. Values on the y-axis are reported as Ct
× (−1). White boxes: healthy subjects; light gray boxes: PD
patients. Samples analysed: 30 CTRL; 31 PD. Statistical
significance was evaluated by the Wilcoxon rank sum test
(p < 0.05). ∗Part of the name of the microRNA according with
microRNA nomenclature.
FIGURE 3 | Box and Whisker plot of DE cmiRNAs validated
after single TaqMan assays in MSA patients compared to
healthy controls. Values on the y-axis are reported as Ct
× (−1). White boxes: healthy patients; dark gray boxes: MSA
patients. Samples analysed: 30 CTRL; 34 MSA. Statistical
significance was evaluated by the Wilcoxon rank sum test
(p < 0.05). ∗Part of the name of the microRNA according with
microRNA nomenclature.
miRNA TARGETS AND GENE ONTOLOGY ANALYSIS
The different distribution of these miRNAs in serum from PD
and MSA patients is most likely a systemic consequence of the
different physiopathology of these two diseases. In order to evalu-
ate the biological functions of DE miRNAs, we computationally
searched their validated or predicted targets as shown above.
Gene ontologies of miRNA targets were analyzed by FatiGo. This
analysis showed that they are involved in important biological
processes of Parkinson and Parkinsonism physiopathology, as cell
cycle regulation, modulation of apoptosis and post-translational
modifications (Figure 5). Moreover, by using the gene functional
classification tool DAVID, we observed that the targets of DE
miRNAs were mainly expressed in the central nervous system
(CNS) and in other tissues as breast, vascular and digestive sys-
tems and kidney (Figure 6). Taken together, these data suggest
that the circulating DE miRNAs, which we identified, derive from
tissues typically involved in PD and MSA and could be involved
in dysfunctional biological processes of the two diseases.
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FIGURE 4 | Box and Whisker plot of DE cmiRNAs validated after
single TaqMan assays in PD patients compared to MSA patients.
Values on the y-axis are reported as Ct × (−1). Light gray boxes: PD
patients; dark gray boxes: MSA patients. Samples analysed: 34 MSA;
31 PD. Statistical significance was evaluated by the Wilcoxon rank sum
test (p < 0.05).
DISCUSSION
Our study provides the first report of whole serum miRNAs
transcriptome profiling in PD and MSA. First, we conducted a
comprehensive screening of miRNAs expression using a TaqMan
Low density Arrays (TLDAs) and, after that, we performed sin-
gle RT-qPCR assays on a second patient dataset to independently
confirm miRNAs profile data. Our analysis identified eight miR-
NAs differentially expressed in PD and MSA vs. controls and
in PD vs. MSA. Mir-324-3p, miR-24 and miR-223∗ were iden-
tified in the largest number of comparisons. Our results expand
findings from previous studies analyzing miRNAs levels in blood
from PD. All serum cmiRNAs previously implicated in PD (Khoo
et al., 2012; Cardo et al., 2013; Botta-Orfila et al., 2014) were
expressed at detectable levels in our samples, but no significant
statistical differences were observed. Probably, those differences
were related to different inclusion criteria used in our study. For
example, we included patients with less than 6 years’ disease dura-
tion from diagnosis or mild-to-moderate disease stage (Hoehn
and Yahr score > 2.5), while in the study by Botta-Orfila et al.,
Hoehn and Yahr score was 2 and disease duration was higher. A
growing body of evidence shows that miRNA expression changes
with age and also the serum levels of specific miRNAs change
markedly. Otherwise, only a few plasma cmiRNAs previously
implicated in PD (Khoo et al., 2012; Cardo et al., 2013) were
expressed at detectable levels in PD and MSA samples but their
differences were not statistically significant. miRNAs expression
pattern in brain, blood, sputum and urine may be a diagnostic
and prognostic biomarker (Ezzie et al., 2012).
Discrepancies in miRNA expression reported in other stud-
ies may result from technical (e.g., sample preparation) as well
as biological (e.g., tissue) differences. In our study, we focused
on serum not only because it has practical advantages, but also
because it is free of anticoagulants as heparin, (a potent inhibitor
of PCR reactions) (Yokota et al., 1999). It is also important
to note that patient blood and serum may be less affected by
haemolysis, if compared with plasma samples. A recent study
suggests a contribution by blood-cell specific and platelet spe-
cific microRNAs deriving from plasma haemolysis and resulting
in significant variation of microRNA expression (Pritchard et al.,
2012). Inadequate handling of plasma samples could increase
the risk of hemolysis and dilute the quality of downstream data
analysis. By contrast, the standard serum isolation procedure
is relatively more consistent as whole blood samples are set to
coagulate naturally. Thus, data comparison of serum samples
collected at different research centers would be more reliable
(Li and Kowdley, 2012).
DEREGULATION OF CIRCULATING miRNAs IN SYNUCLEINOPATHIES
We observed that the miR-324-3p was upregulated in PD and
MSA patients vs. healthy controls. Liu et al. showed that miR-324-
3p was downregulated in the brain of an embolic stroke model
and its expression may be an indicator of recovery (Liu et al.,
2013). In addition, Stappert et al. observed that this miRNA was
upregulated in neural cells compared to human embryonic stem
cells and further increased upon differentiation (Smirnova et al.,
2005; Stappert et al., 2013). Several studies indicated that miR-
324-3p is underexpressed in brain tumor cells and suggested its
hypothetical role as tumor suppressor (Smirnova et al., 2005;
Ferretti et al., 2008; Stappert et al., 2013). In our study, miR-223∗
was upregulated in PD and MSA patients vs. healthy controls.
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FIGURE 5 | GeneOntologyanalysis of targets fromdifferentially expressedmiRNAs.Overrepresented biological processes ofmiRNA targets. Data are shown
as -log10ofBenjamini andHochberg falsediscovery rate foreach term.TheBluebarsshowednon-informativebiological terms (toogeneric termsorunrelated terms).
To date, there are no data on the physiological and pathological
role of miR-223∗, but there are several reports on the biologi-
cal functions of its sister miRNA, miR-223. Izumi et al. reported
an increase in miR-223 expression after spinal cord injury and
indicated that it could regulate neutrophils in the early phase
after lesion (Izumi et al., 2011). Harraz et al. showed that miR-
223 controls the response to neuronal injury by regulating the
functional expression of the glutamate receptor subunits GluR2
and NR2B in the brain. However, this study revealed a unique
function for miR-223 in the CNS by targeting the AMPAR sub-
unit of GluR2 and the NMDAR subunit of NR2B which, in turn,
control neuronal excitability in response to glutamate (Harraz
et al., 2012). We observed that miR-24 was upregulated in PD and
MSA patients vs. healthy controls and in MSA vs. PD patients.
Dutta et al. showed that miR-24 is upregulated in demyelinated
hippocampi from post-mortem multiple sclerosis brains. They
also found that miR-24 is expressed in mouse hippocampal neu-
rons (Dutta et al., 2013) and cardiac endothelial cells. MiR-24
is also considerably upregulated following myocardial ischemia
(Zhu and Fan, 2012).
cmiRNA DYSREGULATION IN PD PATIENTS
miR-30c was downregulated only in PD patients compared to
healthy controls. Meder et al. showed that blood miR-30c was
upregulated and correlated with infarct sizes (Meder et al., 2011).
A study showed that miR-148b was downregulated in human AD
brain, specifically in the parietal lobe cortex (Nunez-Iglesias et al.,
2010), while another revealed downregulation in both hippocam-
pus and medial frontal gyrus, but not in cerebellum from AD
patients (Cogswell et al., 2008). In addition, Zhou et al. demon-
strated that lithium and valproate regulate miR-30c expression in
primary hippocampal neuronal cultures (Zhou et al., 2009).
cmiRNAs DYSREGULATION IN MSA PATIENTS
Only mir-339-5p was specifically downregulated in MSA, but not
in PD compared with controls. However, mir-339-5p was also
downregulated when PD and MSA patients were pooled together
and compared to healthy controls. This miRNA is downregulated
in mature neurons and associated with the important process of
axon guidance (Liu et al., 2012). Interestingly, miR-339-5p was
also identified as endogenous control for normalization of miR-
NAs in primary medulloblastoma and human neural stem cells
(Genovesi et al., 2012).
DEREGULATED cmiRNAs IN MSA PATIENTS IN COMPARISONWITH PD
SUBJECTS
In our study, we showed that expression levels of miR-24, miR-
34b, and miR-148b were increased in serum from MSA patients
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FIGURE 6 | Tissue expression analysis of targets from differentially expressed miRNAs. Tissue-specific overexpression of miRNA targets. Data are shown
as -log10 of Benjamini and Hochberg false discovery rate for each term.
compared to PD subject. Gaughwin et al. showed that miR-
34b was significantly elevated in plasma from Huntington’s dis-
ease gene carriers prior to symptoms onset (Gaughwin et al.,
2011). A recent microRNA profiling study in brains from PD
patients revealed a significant miR-34b decrease (40–65% com-
pared to controls) in affected brain regions, e.g., amygdala,
substantia nigra, and frontal cortex, also showing a modest
trend in the cerebellum. Significant reductions in this miRNA
were also detected in the amygdala, but not in the frontal
cortex of patients with incidental Lewy body disease, a pre-
sumed pre-motor stage of PD. Since these individuals were
asymptomatic during their life and had not received anti-
parkinsonian therapies, these alterations may be part of the
process occurring in the early phases of the disease, rather than
secondary to therapeutic interventions (Miñones-Moyano et al.,
2011).
CIRCULATING miRNAs AS POTENTIAL BIOMARKERS FOR PD
To date, the presence of miRNAs in biological fluids represents
a subject of considerable debate. The most accepted hypothe-
sis proposes that miRNAs are actively secreted in membrane-
bound vesicles (e.g., exosomes, microvesicles) (Valadi et al.,
2007). However, recent studies have shown that the major-
ity of cmiRNAs are present in plasma and serum in a non-
membrane-bound form, protected by complexes comprising
proteins of the Argo family (Wang et al., 2010). Moreover,
the hypothesis that cmiRNAs would be by-products of dead
cells is not to be completely excluded. During the inflamma-
tory processes or apoptosis, neurons could reciprocally exchange
molecular signals through miRNAs or proteins secreted in cere-
brospinal fluid or blood exosomes (Russo et al., 2012; Chang
et al., 2013). This horizontal molecular transfer could also
occur between brain and distant organs via biological flu-
ids. A presumed mechanism involves the transcytosis of exo-
somes across endothelial cells of the blood–brain barrier by
receptor-mediated endocytosis and release of the exosomal cargo
into systemic circulation (Haqqani et al., 2013). Accordingly,
cmiRNAs detected in serum or plasma may be biomarkers
reflecting pathological brain status. Notably, the functional clas-
sification of protein targets of the miRNAs analyzed in our
work showed an overabundance of terms related to CNS,
suggesting that the brain could be the main source of DE
miRNAs.
CONCLUSIONS
This study is the first global miRNAs expression analysis per-
formed in serum of PD andMSA patients. As the effective cellular
function of circulatingmiRNAs remains mostly unknown and the
molecular and phenotypic complexity of PD linger to unravel,
miRNA studies could shed light on its molecular pathogenesis
and possibly serve as disease specific biomarkers. Future prospec-
tive trials on larger cohorts are warranted to confirm whether
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this set of miRNAs can be effectively used for early PD and MSA
diagnosis.
COMPLEMENTARY DATA 1
Table of Delta Ct values obtained from TLDA profiling in serum
from MSA, PD and control patients. Delta Cts were calculated by
normalizing Ct values to median of each TLDA. All miRNAs not
detectable by TLDA were excluded from calculation.
COMPLEMENTARY DATA 2
Expression matrix of 324 miRNAs detectable by TLDA in serum
from MSA, PD, and control patients. Data are shown as Delta
Ct normalized to median of TLDAs. Rows, miRNA; columns,
samples. Delta Ct are shown according to the colored bar shown
below the matrix.
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